118 related articles for article (PubMed ID: 21475207)
1. Trial success spurs planning for rollout of HIV prevention pills.
Dolgin E
Nat Med; 2011 Apr; 17(4):392. PubMed ID: 21475207
[No Abstract] [Full Text] [Related]
2. Emtricitabine/tenofovir disoproxil fumarate.
Dando TM; Wagstaff AJ
Drugs; 2004; 64(18):2075-82; discussion 2083-4. PubMed ID: 15341498
[TBL] [Abstract][Full Text] [Related]
3. FDA paves the way for pre-exposure HIV prophylaxis.
Holmes D
Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
[No Abstract] [Full Text] [Related]
4. A perspective on progress and gaps in HIV prevention science.
Kiser PF; Mesquita PM; Herold BC
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871
[TBL] [Abstract][Full Text] [Related]
5. [PrEP approved in the USA: facts and discussion - permanent chemoprophylaxis for healthy people].
Marcus U
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():42-4. PubMed ID: 23961656
[No Abstract] [Full Text] [Related]
6. Uptake of PrEP for HIV slow among MSM.
Kirby T; Thornber-Dunwell M
Lancet; 2014 Feb; 383(9915):399-400. PubMed ID: 24494225
[No Abstract] [Full Text] [Related]
7. Potential HIV prophylaxis enters Canadian pilot trial.
Lawson J
CMAJ; 2014 May; 186(8):E234. PubMed ID: 24710911
[No Abstract] [Full Text] [Related]
8. The medicalization of HIV prevention: new opportunities beset by old challenges.
Bayer R
Milbank Q; 2014 Sep; 92(3):434-7. PubMed ID: 25199892
[No Abstract] [Full Text] [Related]
9. Single-tablet Quad regimen achieves high rate of virologic suppression.
AIDS Patient Care STDS; 2010 Mar; 24(3):197. PubMed ID: 20214488
[No Abstract] [Full Text] [Related]
10. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
McCormack S; Fidler S; Fisher M; ;
Int J STD AIDS; 2012 Jan; 23(1):1-4. PubMed ID: 22362679
[No Abstract] [Full Text] [Related]
11. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Lyseng-Williamson KA; Scott LJ
Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088
[TBL] [Abstract][Full Text] [Related]
12. Reply to Sachdev et al.
Karris MY; Beekmann SE; Mehta SR; Polgreen PM
Clin Infect Dis; 2014 Jun; 58(12):1788. PubMed ID: 24729555
[No Abstract] [Full Text] [Related]
13. Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs.
Sachdev DD; Stojanovski K; Liu AY; Buchbinder SP; Macalino GE
Clin Infect Dis; 2014 Jun; 58(12):1786-7. PubMed ID: 24729556
[No Abstract] [Full Text] [Related]
14. Truvada for HIV prophylaxis in heterosexual patients.
DeDea L
JAAPA; 2012 Oct; 25(10):14. PubMed ID: 23115862
[No Abstract] [Full Text] [Related]
15. HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.
Cohen J
Science; 2010 Dec; 330(6009):1298-9. PubMed ID: 21127220
[No Abstract] [Full Text] [Related]
16. HIV study yields unexpected preliminary efficacy results.
Traynor K
Am J Health Syst Pharm; 2008 Apr; 65(8):686-8. PubMed ID: 18387889
[No Abstract] [Full Text] [Related]
17. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
18. Preexposure prophylaxis for HIV infection.
Steinbrook R
JAMA; 2012 Sep; 308(9):865-6. PubMed ID: 22820712
[No Abstract] [Full Text] [Related]
19. Treatment options for HIV, AIDS.
FDA Consum; 2004; 38(6):4. PubMed ID: 15675011
[No Abstract] [Full Text] [Related]
20. Still a long wait for approved HIV-protective gel.
Bateman C
S Afr Med J; 2010 Sep; 100(9):560, 562. PubMed ID: 20822637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
